Boston Trust Walden Corp Sells 940 Shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY)

Boston Trust Walden Corp lessened its stake in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 8.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 10,650 shares of the medical instruments supplier’s stock after selling 940 shares during the period. Boston Trust Walden Corp’s holdings in DENTSPLY SIRONA were worth $288,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of XRAY. UMB Bank n.a. raised its position in DENTSPLY SIRONA by 430.3% during the 3rd quarter. UMB Bank n.a. now owns 928 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 753 shares during the last quarter. LRI Investments LLC raised its position in DENTSPLY SIRONA by 82.7% during the 2nd quarter. LRI Investments LLC now owns 1,246 shares of the medical instruments supplier’s stock valued at $31,000 after purchasing an additional 564 shares during the last quarter. Rothschild Investment LLC bought a new position in DENTSPLY SIRONA during the 2nd quarter valued at approximately $32,000. Allworth Financial LP raised its position in DENTSPLY SIRONA by 40.2% during the 3rd quarter. Allworth Financial LP now owns 2,179 shares of the medical instruments supplier’s stock valued at $59,000 after purchasing an additional 625 shares during the last quarter. Finally, Central Pacific Bank Trust Division bought a new position in DENTSPLY SIRONA during the 1st quarter valued at approximately $64,000. Institutional investors own 95.70% of the company’s stock.

Analysts Set New Price Targets

XRAY has been the subject of a number of recent analyst reports. Needham & Company LLC lowered their price target on DENTSPLY SIRONA from $34.00 to $29.00 and set a “buy” rating for the company in a research report on Friday. Evercore ISI lowered their price target on DENTSPLY SIRONA from $29.00 to $27.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. Robert W. Baird lowered their price target on DENTSPLY SIRONA from $33.00 to $31.00 and set a “neutral” rating for the company in a research report on Monday, July 22nd. Stifel Nicolaus reduced their target price on DENTSPLY SIRONA from $30.00 to $28.00 and set a “hold” rating on the stock in a report on Thursday, July 18th. Finally, Barrington Research reiterated an “outperform” rating and set a $36.00 target price on shares of DENTSPLY SIRONA in a report on Friday, September 20th. Five equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $32.67.

DENTSPLY SIRONA Stock Performance

DENTSPLY SIRONA stock opened at $23.31 on Monday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.87 and a current ratio of 1.33. The stock’s 50 day moving average is $25.22 and its 200 day moving average is $26.43. DENTSPLY SIRONA Inc. has a twelve month low of $22.85 and a twelve month high of $37.60.

DENTSPLY SIRONA (NASDAQ:XRAY) last posted its quarterly earnings results on Wednesday, July 31st. The medical instruments supplier reported $0.49 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.01). The company had revenue of $984.00 million during the quarter, compared to analysts’ expectations of $993.61 million. DENTSPLY SIRONA had a positive return on equity of 11.86% and a negative net margin of 4.75%. The business’s quarterly revenue was down 4.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.51 EPS. As a group, sell-side analysts predict that DENTSPLY SIRONA Inc. will post 1.98 earnings per share for the current fiscal year.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.